evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

115 questions · 120 findings · 58 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 34 · 28.3%GRADE not reported 5 · 4.2%Very low 23 · 19.2%Low 32 · 26.7%Moderate 15 · 12.5%High 11 · 9.2%

Low molecular weight heparin vs vitamin K antagonist (VKA)

All‐cause mortality (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters

Low‐molecular‐weight heparin (LMWH) showed no clear difference in all‐cause mortality (up to 3 months) compared with vitamin K antagonist (VKA) (low certainty).

1 finding from 1 review

Low molecular weight heparin vs vitamin K antagonist secondary prophylaxis

All‐cause mortality (time‐to‐event) · patients with cancer with venous thromboembolism

Low molecular weight heparin secondary prophylaxis showed no clear difference in all‐cause mortality (time‐to‐event) compared with vitamin K antagonist secondary prophylaxis (low certainty).

1 finding from 1 review

Low molecular weight heparin vs vitamin K antagonist secondary prophylaxis

All‐cause mortality (main analysis ‐ active cancer) · patients with cancer with venous thromboembolism

Low molecular weight heparin secondary prophylaxis showed no clear difference in all‐cause mortality (main analysis ‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (low certainty).

1 finding from 1 review

Intervention not reported

All‐cause mortality low risk of bias Mortality · patients with preventing hepatitis A.

The intervention showed no clear difference in all‐cause mortality low risk of bias Mortality (high certainty).

1 finding from 1 review

FIBRINOGEN: Therapeutic trials: intervention vs inactive control

All‐cause mortality Up to 28 days following admission · the prevention and treatment of bleeding in patients without haemophilia

FIBRINOGEN: Therapeutic trials: intervention showed no clear difference in all‐cause mortality Up to 28 days following admission compared with inactive Control (moderate certainty).

1 finding from 1 review

IVIg vs placebo or no intervention

28‐Day all cause mortality (adult studies) · adult patients with sepsis, severe sepsis and septic shock

Polyclonal intravenous immunoglobulin (IVIG) showed no clear difference in low risk of bias adult studies, by type of polyclonal IVIG,… compared with placebo or no intervention (high certainty).

3 findings from 1 review

IVIg vs placebo or no intervention

All‐cause mortality, neonates, standard polyclonal IVIG · neonates with sepsis, severe sepsis and septic shock

Polyclonal intravenous immunoglobulin (IVIG) showed no clear difference in low risk of bias neonate studies, mortality all‐cause ‐ standard IVIG compared with placebo or no intervention (high certainty).

1 finding from 1 review

Higher vs lower FiO2 or targets of arterial oxygenation

All‐cause mortality: range 1 mo to 1 y · adults admitted to the ICU

It is very uncertain whether higher changes all‐cause mortality: range 1 mo to 1 y compared with lower FiO2 or targets of arterial oxygenation (very low certainty).

1 finding from 1 review

Summary of Findings Table ‐ Chronic non‐invasive ventilation vs standard treatment following a severe exacerbation

All‐cause mortality · post‐exacerbation COPD

Summary of Findings Table ‐ Chronic non‐invasive ventilation showed no clear difference in all‐cause mortality compared with standard treatment following a severe exacerbation (low certainty).

1 finding from 1 review

Aspirin vs low molecular weight heparin

All‐cause mortality · ambulatory patients with multiple myeloma receiving immunomodulatory agents

It is very uncertain whether aspirin (ASA) changes all‐cause mortality compared with low molecular weight heparin (LMWH) (very low certainty).

2 findings from 1 review